Daptomycin Hospira

Country: Kesatuan Eropah

Bahasa: Inggeris

Sumber: EMA (European Medicines Agency)

Beli sekarang

Risalah maklumat Risalah maklumat (PIL)
06-04-2022
Ciri produk Ciri produk (SPC)
06-04-2022
Laporan Penilaian Awam Laporan Penilaian Awam (PAR)
11-12-2019

Bahan aktif:

daptomycin

Boleh didapati daripada:

Pfizer Europe MA EEIG

Kod ATC:

J01XX09

INN (Nama Antarabangsa):

daptomycin

Kumpulan terapeutik:

Antibacterials for systemic use,

Kawasan terapeutik:

Soft Tissue Infections; Skin Diseases, Bacterial

Tanda-tanda terapeutik:

Daptomycin is indicated for the treatment of the following infections.Adult and paediatric (1 to 17 years of age) patients with complicated skin and soft-tissue infections (cSSTI).Adult patients with right-sided infective endocarditis (RIE) due to Staphylococcus aureus. It isrecommended that the decision to use daptomycin should take into account the antibacterial susceptibility of the organism and should be based on expert advice.Adult and paediatric (1 to 17 years of age) patients with Staphylococcus aureus bacteraemia (SAB).In adults, use in bacteraemia should be associated with RIE or with cSSTI, while in paediatric patients, use in bacteraemia should be associated with cSSTI.Daptomycin is active against Gram positive bacteria only. In mixed infections where Gram negative and/or certain types of anaerobic bacteria are suspected, daptomycin should be co-administered with appropriate antibacterial agent(s).Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Ringkasan produk:

Revision: 13

Status kebenaran:

Authorised

Tarikh kebenaran:

2017-03-22

Risalah maklumat

                                38
B. PACKAGE LEAFLET
39
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
DAPTOMYCIN HOSPIRA 350 MG POWDER FOR SOLUTION FOR INJECTION/INFUSION
daptomycin
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS IMPORTANT
INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them, even
if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or nurse. This
includes any possible side effects not
listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Daptomycin Hospira is and what it is used for
2.
What you need to know before you are given Daptomycin Hospira
3.
How Daptomycin Hospira is given
4.
Possible side effects
5.
How to store Daptomycin Hospira
6.
Contents of the pack and other information
1.
WHAT DAPTOMYCIN HOSPIRA IS AND WHAT IT IS USED FOR
The active substance in Daptomycin Hospira powder for solution for
injection/infusion is daptomycin.
Daptomycin is an antibacterial that can stop the growth of certain
bacteria. Daptomycin Hospira is used in
adults and in children and adolescents (age from 1 to 17 years) to
treat infections of the skin and the
tissues below the skin. It is also used to treat infections in the
blood when associated with skin infection.
Daptomycin Hospira is also used in adults to treat infections in the
tissues that line the inside of the heart
(including heart valves) which are caused by a type of bacteria called
_Staphylococcus aureus._
It is also
used to treat infections in the blood caused by the same type of
bacteria when associated with heart
infection.
Depending on the type of infection(s) that you have, your doctor may
also prescribe other antibacterials
while you are receiving treatment with Daptomycin Hospira.
2.
WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN DAPTOMYCIN HOSPIRA
YOU SHOULD NOT BE GIVEN DAPTOMYCIN HOSPIRA
If 
                                
                                Baca dokumen lengkap
                                
                            

Ciri produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Daptomycin Hospira 350 mg powder for solution for injection/infusion
Daptomycin Hospira 500 mg powder for solution for injection/infusion
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Daptomycin Hospira 350 mg powder for solution for injection/infusion
Each vial contains 350 mg daptomycin.
One mL provides 50 mg of daptomycin after reconstitution with 7 mL of
sodium chloride 9 mg/mL
(0.9%) solution for injection.
Daptomycin Hospira 500 mg powder for solution for injection/infusion
Each vial contains 500 mg daptomycin.
One mL provides 50 mg of daptomycin after reconstitution with 10 mL of
sodium chloride 9 mg/mL
(0.9%) solution for injection.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Daptomycin Hospira 350 mg powder for solution for injection/infusion
Powder for solution for injection/infusion.
A light yellow to light brown lyophilised cake or powder.
Daptomycin Hospira 500 mg powder for solution for injection/infusion
Powder for solution for injection/infusion.
A light yellow to light brown lyophilised cake or powder.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Daptomycin is indicated for the treatment of the following infections
(see sections 4.4 and 5.1).
-
Adult and paediatric (1 to 17 years of age) patients with complicated
skin and soft-tissue infections
(cSSTI).
-
Adult patients with right-sided infective endocarditis (RIE) due to
_Staphylococcus aureus. _
It is
recommended that the decision to use daptomycin should take into
account the antibacterial
susceptibility of the organism and should be based on expert advice
(see sections 4.4 and 5.1).
-
Adult and paediatric (1 to 17 years of age) patients with
_ Staphylococcus aureus _
bacteraemia (SAB).
In adults, use in bacteraemia should be associated with RIE or with
cSSTI, while in paediatric
patients, use in bacteraemia should be associated with cSSTI.
3
Daptomycin is active against Gram positive bacteria only (see section
5.1). In mixed infec
                                
                                Baca dokumen lengkap
                                
                            

Dokumen dalam bahasa lain

Risalah maklumat Risalah maklumat Bulgaria 06-04-2022
Ciri produk Ciri produk Bulgaria 06-04-2022
Laporan Penilaian Awam Laporan Penilaian Awam Bulgaria 18-04-2018
Risalah maklumat Risalah maklumat Sepanyol 06-04-2022
Ciri produk Ciri produk Sepanyol 06-04-2022
Laporan Penilaian Awam Laporan Penilaian Awam Sepanyol 18-04-2018
Risalah maklumat Risalah maklumat Czech 06-04-2022
Ciri produk Ciri produk Czech 06-04-2022
Laporan Penilaian Awam Laporan Penilaian Awam Czech 18-04-2018
Risalah maklumat Risalah maklumat Denmark 06-04-2022
Ciri produk Ciri produk Denmark 06-04-2022
Laporan Penilaian Awam Laporan Penilaian Awam Denmark 18-04-2018
Risalah maklumat Risalah maklumat Jerman 06-04-2022
Ciri produk Ciri produk Jerman 06-04-2022
Laporan Penilaian Awam Laporan Penilaian Awam Jerman 18-04-2018
Risalah maklumat Risalah maklumat Estonia 06-04-2022
Ciri produk Ciri produk Estonia 06-04-2022
Laporan Penilaian Awam Laporan Penilaian Awam Estonia 18-04-2018
Risalah maklumat Risalah maklumat Greek 06-04-2022
Ciri produk Ciri produk Greek 06-04-2022
Laporan Penilaian Awam Laporan Penilaian Awam Greek 18-04-2018
Risalah maklumat Risalah maklumat Perancis 06-04-2022
Ciri produk Ciri produk Perancis 06-04-2022
Laporan Penilaian Awam Laporan Penilaian Awam Perancis 18-04-2018
Risalah maklumat Risalah maklumat Itali 06-04-2022
Ciri produk Ciri produk Itali 06-04-2022
Laporan Penilaian Awam Laporan Penilaian Awam Itali 18-04-2018
Risalah maklumat Risalah maklumat Latvia 06-04-2022
Ciri produk Ciri produk Latvia 06-04-2022
Laporan Penilaian Awam Laporan Penilaian Awam Latvia 18-04-2018
Risalah maklumat Risalah maklumat Lithuania 06-04-2022
Ciri produk Ciri produk Lithuania 06-04-2022
Laporan Penilaian Awam Laporan Penilaian Awam Lithuania 18-04-2018
Risalah maklumat Risalah maklumat Hungary 06-04-2022
Ciri produk Ciri produk Hungary 06-04-2022
Laporan Penilaian Awam Laporan Penilaian Awam Hungary 18-04-2018
Risalah maklumat Risalah maklumat Malta 06-04-2022
Ciri produk Ciri produk Malta 06-04-2022
Laporan Penilaian Awam Laporan Penilaian Awam Malta 18-04-2018
Risalah maklumat Risalah maklumat Belanda 06-04-2022
Ciri produk Ciri produk Belanda 06-04-2022
Laporan Penilaian Awam Laporan Penilaian Awam Belanda 18-04-2018
Risalah maklumat Risalah maklumat Poland 06-04-2022
Ciri produk Ciri produk Poland 06-04-2022
Laporan Penilaian Awam Laporan Penilaian Awam Poland 18-04-2018
Risalah maklumat Risalah maklumat Portugis 06-04-2022
Ciri produk Ciri produk Portugis 06-04-2022
Laporan Penilaian Awam Laporan Penilaian Awam Portugis 18-04-2018
Risalah maklumat Risalah maklumat Romania 06-04-2022
Ciri produk Ciri produk Romania 06-04-2022
Laporan Penilaian Awam Laporan Penilaian Awam Romania 18-04-2018
Risalah maklumat Risalah maklumat Slovak 06-04-2022
Ciri produk Ciri produk Slovak 06-04-2022
Laporan Penilaian Awam Laporan Penilaian Awam Slovak 18-04-2018
Risalah maklumat Risalah maklumat Slovenia 06-04-2022
Ciri produk Ciri produk Slovenia 06-04-2022
Laporan Penilaian Awam Laporan Penilaian Awam Slovenia 18-04-2018
Risalah maklumat Risalah maklumat Finland 06-04-2022
Ciri produk Ciri produk Finland 06-04-2022
Laporan Penilaian Awam Laporan Penilaian Awam Finland 18-04-2018
Risalah maklumat Risalah maklumat Sweden 06-04-2022
Ciri produk Ciri produk Sweden 06-04-2022
Laporan Penilaian Awam Laporan Penilaian Awam Sweden 18-04-2018
Risalah maklumat Risalah maklumat Norway 06-04-2022
Ciri produk Ciri produk Norway 06-04-2022
Risalah maklumat Risalah maklumat Iceland 06-04-2022
Ciri produk Ciri produk Iceland 06-04-2022
Risalah maklumat Risalah maklumat Croat 06-04-2022
Ciri produk Ciri produk Croat 06-04-2022
Laporan Penilaian Awam Laporan Penilaian Awam Croat 18-04-2018

Cari amaran yang berkaitan dengan produk ini